期刊
JOURNAL OF NUCLEAR MEDICINE
卷 58, 期 1, 页码 81-84出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.116.181800
关键词
oncology: GU; PET; androgen receptor; PSMA PET; prostate cancer
资金
- Radiological Society of North America
- Department of Radiology and Biomedical Imaging, UCSF
- GE Healthcare
- Prostate Cancer Foundation
- National Institutes of Health [R00CA172695, 1R01CA17661]
- Department of Defense Idea Development Award [PC140107]
- UCSF Academic Senate
- Department of Defense Prostate Cancer Research Program [PC151060]
- National Cancer Institute of the National Institutes of Health [P30CA082103]
- ORIC Pharmaceuticals, Inc.
The purpose of this work was to evaluate the effect of androgen receptor (AR) inhibition on prostate-specific membrane antigen (PSMA) uptake imaged using 68Ga-PSMA-11 PET in a mouse xenograft model and in a patient with castration-sensitive prostate cancer. Methods: We imaged 3 groups of 4 mice bearing LNCaPAR xenografts before and 7 d after treatment with ARN-509, orchiectomy, or control vehicle. Additionally, we imaged one patient with castration-sensitive prostate cancer before and 4 wk after treatment with androgen deprivation therapy (ADT). Uptake on pre-and posttreatment imaging was measured and compared. Results: PSMA uptake increased 1.5-to 2.0-fold in the xenograft mouse model after treatment with both orchiectomy and ARN-509 but not with vehicle. Patient imaging demonstrated a 7-fold increase in PSMA uptake after the initiation of ADT. Thirteen of 22 lesions in the imaged patient were visualized on PSMA PET only after treatment with ADT. Conclusion: Inhibition of the AR can increase PSMA expression in prostate cancer metastases and increase the number of lesions visualized using PSMA PET. The effect seen in cell and animal models can be recapitulated in humans. A better understanding of the temporal changes in PSMA expression is needed to leverage this effect for both improved diagnosis and improved therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据